Intellectual PropertySilence has built a strong and comprehensive intellectual property portfolio which encompasses both proprietary and in-licensed patents and patent applications.
General IP strategy
Silence has built a strong and comprehensive intellectual property portfolio which encompasses both proprietary and in-licensed patents and patent applications. This portfolio covers all aspects of siRNA based therapeutics such as targets, specific siRNA sequences and design rules for such specific siRNA sequences, stabilization of siRNA sequences and delivery systems. As individual siRNA based therapeutic products developed by Silence realize several of these aspects, a very strong patent protection is provided for the individual therapeutic product.
Specific siRNA molecules
Silence is seeking patent protection for siRNA molecules having a specific nucleotide sequence. These specific siRNA sequence molecules are the result of both Silence's know-how and access to proprietary design rules. Apart from being monopolized by its sequence as such, the know-how and design rules factually exclude third parties from generating similar siRNA molecules thus extending the scope of protection beyond the specific siRNA sequences.
Apart from monopolizing specific siRNA molecules, Silence has rights to any siRNA molecule irrespective of the specific nucleotides sequence for distinct targets and the use thereof in the treatment of certain diseases related to such targets.
Exclusive structural features
Silence's specific siRNA molecules exhibit unique structural features which, irrespective of their individual nucleotide sequence, bar third parties from commercializing this kind of molecules. Such unique structural features are the positional modification of the siRNA molecule (AtuRNAi®) and the use of blunt end molecules which are both subject to proprietary patents and patent applications.
Stabilization technology - AtuRNAi®
AtuRNAi® is a proprietary technology of Silence with which an individual siRNA molecule is stabilized against degradation in a patient. This stabilization is achieved by a positional modification of the nucleotides of the individual siRNA molecule, where every second nucleotide of the siRNA molecule is modified by a therapeutically acceptable methoxy group.
Stabilization technology - blunt ends
Silence discovered very early that in contrast to what has been widely accepted as a paradigm in the field of siRNA, blunt end siRNA molecules are highly effective and stable when used in vivo, and is using this kind of siRNA molecules successfully in clinical trials.
Silence has also proprietary rights to a lipid component which is the core of several delivery systems developed and used by Silence (AtuPLEX®, DACC and others). The delivery systems as such are subject to various patent families extending the scope of protection to the specific composition and use of the delivery systems.
Licenses from third parties
Silence has in-licensed intellectual property rights related to siRNA technology from Nobel laureates Andres Z. Fire and Craig C. Mellow (The Carnegie Institute of Washington) as well as from Phillip D. Zamore (University of Massachusetts).